Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan with Radiation and BCNU in Glioblastoma
NCT00027612Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jul 2002
- Primary completion
- Oct 2006
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in glioblastoma multiforme (GBM), sponsored by Cancer and Leukemia Group B. Primary endpoint: Survival at 52 weeks. Started Jul 2002; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00027612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027612.